Researchers may have hit 'gold' when it comes to the treatment of multiple sclerosis. An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials in terms of improvements in MS symptoms. The 'catalytically active' liquid, developed by Clene Nanomedicine in South Carolina, can cross the blood-brain barrier to help improve cellular energy and restore neurological function, according to researchers.
Doctors at the University of Sydney presented the Phase 2 clinical trial findings at the American Academy of Neurology’s annual meeting earlier in April 2024. The clinical trials included 78 patients who had relapsing multiple sclerosis. The gold liquid suspension was found to have a 'profound clinical benefit,' with the patients experiencing physical improvements not achieved in prior trials.
This is a non-inflammatory component of the disease, where patients would worsen in vision and cognitive abilities,' Sergott, who was involved in the clinical trial for CNM-Au8, told Fox News Digital. Researchers suspected that something to do with mitochondria — parts of cells that are responsible for supplying those cells with energy — was causing these patients’ symptoms.
Looking ahead, there is the potential for the 'liquid gold' medication to help treat symptoms of other neurological disorders, including amyotrophic lateral sclerosis , Alzheimer’s and Parkinson’s, according to Sergott — but the focus is on MS for now. 'We don't want to get too far ahead of ourselves, but there is plenty of information to support trying this in other diseases.
And now gold-containing agents are being studied in MS and ALS.' While the latest study is small, Siegel said, it 'looks promising in terms of modifying disease and improving thinking and vision, which can be affected in the early stages of MS.' He added, 'More research with larger numbers needs to be done to be conclusive.' Dr.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: physorg_com - 🏆 388. / 55 Read more »
Source: PsychToday - 🏆 714. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: washingtonpost - 🏆 95. / 72 Read more »
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: commondreams - 🏆 530. / 51 Read more »